147 related articles for article (PubMed ID: 7540196)
1. The disease associations of the antibody response against the Epstein-Barr virus transactivator protein ZEBRA can be separated into different epitopes.
Tedeschi R; Foong YT; Cheng HM; dePaoli P; Lehtinen T; Elfborg T; Dillner J
J Gen Virol; 1995 Jun; 76 ( Pt 6)():1393-400. PubMed ID: 7540196
[TBL] [Abstract][Full Text] [Related]
2. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
[TBL] [Abstract][Full Text] [Related]
3. Detection of IgA against Epstein-Barr virus BZLF-1 replication activator (ZEBRA) in sera of nasopharyngeal carcinoma patients with a recombinant ZEBRA protein.
Shu CH; Tu TY; Lin LS; Ro LH; Lo MS; Huang CH; Chen KY; Liu WT
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jun; 62(6):350-5. PubMed ID: 10389292
[TBL] [Abstract][Full Text] [Related]
4. Enzyme-linked immunosorbent assay for antibodies to ZEBRA, an Epstein-Barr trans-activator.
Maréchal V; Meyohas MC; Joab I; Gaha S; Giot JF; Sergeant A; Nicolas JC
Res Virol; 1993; 144(5):397-404. PubMed ID: 8284517
[TBL] [Abstract][Full Text] [Related]
5. Linear epitopes of the replication-activator protein of Epstein-Barr virus recognised by specific serum IgG in nasopharyngeal carcinoma.
Cheng HM; Foong YT; AbuSamah AJ; Dillner J; Sam CK; Prasad U
Cancer Immunol Immunother; 1995 Apr; 40(4):251-6. PubMed ID: 7750123
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of antibodies to the Epstein-Barr virus immediate early gene product ZEBRA by a new enzyme-linked immunosorbent assay.
Yamauchi Y; Tachiband Y; Maeda A; Wakiguchi H; Usui M; Kurata T; Sairenji T
Intervirology; 1998; 41(6):278-84. PubMed ID: 10325538
[TBL] [Abstract][Full Text] [Related]
7. Detection of anti-Epstein-Barr-virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma.
Joab I; Nicolas JC; Schwaab G; de-Thé G; Clausse B; Perricaudet M; Zeng Y
Int J Cancer; 1991 Jul; 48(5):647-9. PubMed ID: 1649137
[TBL] [Abstract][Full Text] [Related]
8. A high incidence of serum IgG antibodies to the Epstein-Barr virus replication activator protein in nasopharyngeal carcinoma.
Mathew A; Cheng HM; Sam CK; Joab I; Prasad U; Cochet C
Cancer Immunol Immunother; 1994 Jan; 38(1):68-70. PubMed ID: 8299121
[TBL] [Abstract][Full Text] [Related]
9. Antibody and antibody-dependent cellular cytotoxicity responses against the BamHI A rightward open-reading frame-1 protein of Epstein-Barr virus (EBV) in EBV-associated disorders.
Tanner JE; Wei MX; Alfieri C; Ahmad A; Taylor P; Ooka T; Menezes J
J Infect Dis; 1997 Jan; 175(1):38-46. PubMed ID: 8985194
[TBL] [Abstract][Full Text] [Related]
10. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma.
Dardari R; Khyatti M; Benider A; Jouhadi H; Kahlain A; Cochet C; Mansouri A; El Gueddari B; Benslimane A; Joab I
Int J Cancer; 2000 Apr; 86(1):71-5. PubMed ID: 10728597
[TBL] [Abstract][Full Text] [Related]
11. Immune response to different sequences of the EBNA I molecule in Epstein-Barr virus-related disorders and in autoimmune diseases.
Marchini B; Dolcher MP; Sabbatini A; Klein G; Migliorini P
J Autoimmun; 1994 Apr; 7(2):179-91. PubMed ID: 7518683
[TBL] [Abstract][Full Text] [Related]
12. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
[TBL] [Abstract][Full Text] [Related]
13. A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma.
Yip TT; Ngan RK; Lau WH; Poon YF; Joab I; Cochet C; Cheng AK
Cancer; 1994 Nov; 74(9):2414-24. PubMed ID: 7922994
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus (EBV) replicative gene expression in tumour cells of AIDS-related non-Hodgkin's lymphoma in relation to CD4 cell number and antibody titres to EBV.
Brousset P; Drouet E; Schlaifer D; Icart J; Payen C; Meggetto F; Marchou B; Massip P; Delsol G
AIDS; 1994 May; 8(5):583-90. PubMed ID: 7914731
[TBL] [Abstract][Full Text] [Related]
15. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases.
Meij P; Vervoort MB; Aarbiou J; van Dissel P; Brink A; Bloemena E; Meijer CJ; Middeldorp JM
J Infect Dis; 1999 May; 179(5):1108-15. PubMed ID: 10191211
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473
[TBL] [Abstract][Full Text] [Related]
17. Comparison of in situ hybridization using different nonisotopic probes for detection of Epstein-Barr virus in nasopharyngeal carcinoma and immunohistochemical correlation with anti-latent membrane protein antibody.
Brousset P; Butet V; Chittal S; Selves J; Delsol G
Lab Invest; 1992 Oct; 67(4):457-64. PubMed ID: 1331609
[TBL] [Abstract][Full Text] [Related]
18. Cellular immunity in infectious mononucleosis. II. Specific reactivity to Epstein-Barr Virus antigens and correlation with clinical and hematologic parameters.
Nikoskelainen J; Ablashi DV; Isenberg RA; Neel EU; Miller RG; Stevens DA
J Immunol; 1978 Oct; 121(4):1239-44. PubMed ID: 81224
[TBL] [Abstract][Full Text] [Related]
19. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
[TBL] [Abstract][Full Text] [Related]
20. Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases.
Xu J; Ahmad A; D'Addario M; Knafo L; Jones JF; Prasad U; Dolcetti R; Vaccher E; Menezes J
J Immunol; 2000 Mar; 164(5):2815-22. PubMed ID: 10679125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
